When patients ask what they are trying to support with regenerative treatment, the honest answer is usually two proteins. Collagen and elastin are the structural backbone of the dermis. They are produced by the same cell, organised in the same extracellular matrix, and degraded by overlapping pathways, but they do very different jobs. Understanding the difference clarifies almost every conversation about skin quality, ageing and what considered treatment can and cannot influence.
What collagen does
Collagen is the most abundant protein in the human body and the dominant structural protein in skin. In the dermis it forms long, rope-like fibrils, predominantly type I with smaller amounts of type III, that give skin its tensile strength and bulk. Healthy young dermis is approximately seventy percent collagen by dry weight. When patients describe skin that feels firm and full, they are largely describing collagen content.
Collagen is produced by fibroblasts, the resident worker cells of the dermis. Production peaks in early adulthood and declines steadily thereafter. A frequently cited review in the British Journal of Dermatology estimates that dermal collagen content declines by approximately one percent per year of adult life in unprotected skin, with significantly greater losses associated with chronic UV exposure, smoking and oestrogen decline at menopause.
What elastin does
Elastin is the protein that allows skin to return to its original shape after being stretched. It is woven through the dermis as fine, branching fibres that act, in mechanical terms, like the elastic threads in a knitted fabric. Without it, skin would behave like paper: it would deform under load and stay deformed. The simple pinch test that many clinicians use, where the skin on the back of the hand is gently lifted and timed as it returns to position, is in effect a clinical assessment of elastin function.
Elastin is also produced by fibroblasts, but the production schedule is very different to collagen. The body lays down the majority of its functional elastin during fetal development and early childhood. After that, elastin production largely stops. The elastic network you carry into adulthood is, with limited exceptions, the network you keep.
Why this matters for treatment
This asymmetry has practical consequences. Collagen, because it continues to be produced throughout life, is the protein most realistically influenced by in-clinic regenerative approaches. Modalities such as medical skin needling, bio-stimulators and regulated energy-based devices aim to stimulate fibroblasts to lay down new collagen in response to controlled signals. The evidence base for collagen induction is substantial.
Elastin is more difficult. Because adult fibroblasts produce very little new elastin, restoring the elastic network of young skin is not a realistic clinical target. What considered treatment can do is protect the existing network from further degradation, support overall dermal quality so the elastin that is present functions in a healthier matrix, and, in some cases, modestly improve organisation of newly deposited elastic fibres around micro-injury sites.
The matrix they live in
Collagen and elastin do not act alone. They sit inside an extracellular matrix that includes hyaluronic acid, proteoglycans and a population of fibroblasts that maintain and renew the system. Hyaluronic acid binds water at a remarkable ratio, contributing to skin's plumpness and supporting the matrix in which the structural proteins are organised. When considered treatments such as bio-remodelling injectables aim to improve hydration and stimulate fibroblast activity, the goal is to support the entire matrix, not any single component.
What degrades them
The contributors to collagen and elastin degradation are largely the same, and they are largely modifiable.
- · UV radiation, which activates matrix metalloproteinases that break down both collagen and elastin and is consistently identified as the largest contributor to dermal degradation in fair-skinned populations.
- · Smoking, which is associated with reduced collagen production and abnormal elastin deposition.
- · Chronic systemic inflammation, including poorly controlled metabolic disease.
- · Oestrogen decline at menopause, which is associated with measurable losses in dermal collagen in the years immediately after the menopause transition.
- · Significant weight fluctuation, which loads and unloads the dermal matrix repeatedly.
Collagen is the protein time will negotiate with. Elastin is the protein time tends to keep.
What this means in practice
A patient who understands the difference between collagen and elastin tends to make better decisions about their own care. They prioritise daily UV protection rather than treating it as optional. They take topical work seriously in years when nothing visible seems to be happening. They are more receptive to the cadence of regenerative treatment, which builds slowly over months as fibroblasts respond to repeated, controlled signals, and they are less likely to be drawn to single interventions that promise to restore elasticity they cannot actually replace.
Realistic expectations are not a compromise. They are the foundation on which long-term skin quality is built.
Building your plan
Whether any treatment is appropriate for you, and how a plan to support skin quality should be structured, is determined in a one-on-one medical consultation. Your practitioner will examine your skin, review your medical history, discuss your goals and explain the risks of any treatment that may be considered. All cosmetic procedures carry risks and outcomes vary between individuals.
This article is general information and is not medical advice.